ArticleClinical rheumatology2019
On demand use of anakinra for attacks of familial Mediterranean fever (FMF).
Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.Seminars in arthritis and rheumatism · 2026Observational
- What do patients do during a familial Mediterranean fever attack? Their strategies and associated factors.Internal and emergency medicine · 2025Article
- The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever.Rheumatology international · 2024Article
- Treat-to-target strategies for the management of familial Mediterranean Fever in children.Pediatric rheumatology online journal · 2023Article
- The pyrin inflammasome, a leading actor in pediatric autoinflammatory diseases.Frontiers in immunology · 2023Review
- The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.International journal of molecular sciences · 2022Review
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Patient with Familial Mediterranean Fever.Mediterranean journal of hematology and infectious diseases · 2022Article
- The Enigma of Prodromes in Hereditary Angioedema (HAE).Clinical reviews in allergy & immunology · 2021Review
- New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA).Clinical reviews in allergy & immunology · 2021Article
- Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists.Clinical rheumatology · 2021Article
- Familial Mediterranean fever, from pathogenesis to treatment: a contemporary reviewTurkish journal of medical sciences · 2020Review
- Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.Frontiers in immunology · 2020Review
- The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.Frontiers in immunology · 2020Review
- Molecularly Distinct NLRP3 Inducers Mediate Diverse Ratios of Interleukin-1Mediators of inflammation · 2020Article
- Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort.Frontiers in pharmacology · 2020Article
- Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis.Frontiers in neurology · 2020Article
- Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).Orphanet journal of rare diseases · 2019Review
- Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the efficacy of on-demand use of anakinra in patients with crFMF. The Gazi FMF cohort was established in the year 2010, and from that date, 689 patients with FMF diagnosed according to the Tel Hashomer criteria were registered. Attack type, duration, severity, and their impact on life were collected either by disease diaries or a mobile phone application (FMF AIDD, AppStore, and Playstore). A retrospective cohort analysis was made from records of patients who have ever been treated with IL-1 inhibitors. A total of 78 patients were treated with IL-1 inhibitors in our cohort. Among these, 15 patients were identified who received on-demand anakinra. Rationale for on-demand use was prominent prodrome or trigger for attacks and patient's personal claim. Six patients were switched from regular use and nine were directly started as on-demand use. All were using background colchicine in maximum tolerated doses. None of the patients had evidence of persistently elevated acute phase reactants or proteinuria. The median duration of on-demand anakinra use was 6 (3-36) months. Pre- and post- on-demand anakinra periods were compared. Patient reported attack severity (p = 0.002), duration (p = 0.001), frequency (p = 0.001), absenteeism (p = 0.002), and presenteeism (p = 0.002) were significantly improved. On-demand anakinra prevented progression of prodromes to full-blown attacks which was demonstrated by decrease in the rate of attack/prodrome ratio (p = 0.02). On-demand anakinra can be continued in ten subjects on long-term. On-demand anakinra significantly improved FMF attacks in certain patients which suggest this approach would be of benefit in daily practice in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.